Advicenne was founded in 2007 by experienced industrial scientists and initially developed thanks to “Business Angels” who were won over and convinced by Advicenne’s Business Model. In 2010 Advicenne filed its first 3 patents for an innovative formulation for the treatment of a hereditary orphan disease. In 2011 Advicenne carried out a second funding round for more than €5 million by InnoBio investment funds managed by CDC Entreprises in which iXO Private Equity, the most important French regional independent fund, participates, and private investors. These funds made the performance of the first clinical trials possible. During 2013, Advicenne has concluded its two first in-licensing agreements for anti-epileptic products. Advicenne’s portfolio continued to strengthen with 5 products in clinical development/registration phase and 3 products in R&D. A third funding round has been carried out towards current investors.
2014 has seen important steps forward for Advicenne :
- Liquid suspension of clobazam 1mg/ml, trademark Likozam obtained an early access on the French market through the ATU process.
- Levidcen, coated granules of levetiracetam has been approved by the French agency in October. Both Likozam and Levidcen are indicated for the treatment of Epilepsy.
- Last but not least, the phase III clinical trial of one of Advicenne’s major products has started.
Becoming a leader in the market of pediatric drugs
ADVICENNE’s ambition is to become one of the leading pediatric pharmaceutical companies for the treatment of chronic incapacitating and/or neglected diseases in the fields of the central nervous system and childhood renal diseases.